Literature DB >> 65221

Eight-drug combination chemotherapy (MOPP and ABDV) and local radiotherapy for advanced Hodgkin's Disease.

D C Case, C W Young, L Nisce, B J Lee, B D Clarkson.   

Abstract

Thirty-seven patients with advanced Hodgkin's disease have been treated for greater than or equal to 3 months with a protocol consisting of alternate monthly courses of MOPP (mechlorethamine, Oncovin [vincristine], procarbazine, and prednisone) and ABDV (adriamycin, bleomycin, DTIC, and vinblastine) with local radiotherapy (RT) to areas of originally bulky disease. This therapy produced CR in 19 of 19 previously untreated patients (100%), eight of nine previously treated with RT (89%), and six of nine previously treated with RT and MOPP (67%). The remaining patients are all PRs tending toward CR status. The median time to CR was 3.0 months. The median time in remission to date for the previously untreated patients is 8+ months (2+-14+). After an induction period of eight cycles of chemotherapy patients are maintained on alternate-month treatment continuing the alternating sequence. During this phase three patients have experienced reappearance of disease (one recurrence, one possible second primary lymphoma, and one recurrence in a patient whose original diagnosis is in doubt). The regimen has been well tolerated. All patients were treated as outpatients. Alopecia and neurotoxicity were mild and myelosuppression was moderate. Clinically significant cardiopulmonary toxicity has been limited to mild radiation pneumonitis in one patient and bleomycin pneumonitis which cleared during prednisone in a second patient.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 65221

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  4 in total

1.  Prognostic factors in COPP-treated patients with Hodgkin's disease.

Authors:  W Gassmann; L Perenyi; N Schmitz; W Kayser; H Pralle; H Löffler
Journal:  Blut       Date:  1982-06

2.  Efficacy of combinations of difluoromethylornithine and bleomycin in a mouse model of central nervous system African trypanosomiasis.

Authors:  A B Clarkson; C J Bacchi; G H Mellow; H C Nathan; P P McCann; A Sjoerdsma
Journal:  Proc Natl Acad Sci U S A       Date:  1983-09       Impact factor: 11.205

3.  Adriamycin, bleomycin, vinblastine and imidazole carboxamide (ABVD) therapy for advanced Hodgkin's disease resistant to mustine, vinblastine, procarbazine and prednisolone (MVPP).

Authors:  S B Sutcliffe; P F Wrigley; A G Stansfeld; J S Malpas
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

4.  [Results of treatment with ABVD in C-MOPP-resistant Hodgkin's disease (author's transl)].

Authors:  W Gassmann; L Perenyi; H Pralle; M Graubner; N Schmitz; H Löffler
Journal:  Klin Wochenschr       Date:  1981-03-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.